Reduced disability at five years with early treatment of inflammatory polyarthritis: Results from a large observational cohort, using propensity models to adjust for disease severity

Arthritis and Rheumatism

Volumn 44, Issue 5, 2001, Pages 1033-1042

  Wiles, Nicola J ^a   Lunt, Mark ^a   Barrett, Elizabeth M ^b   Bukhari, Marwan ^a   Silman, Alan J ^a   Symmons, Deborah P M ^a   Dunn, Graham ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b ST MICHAEL'S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; CHLOROQUINE; GOLD; HYDROXYCHLOROQUINE; METHOTREXATE; PENICILLAMINE; SALAZOSULFAPYRIDINE; STEROID;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DISABILITY; DISEASE SEVERITY; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; POLYARTHRITIS; PRIORITY JOURNAL; PROBABILITY; SCORING SYSTEM; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS; DISABILITY EVALUATION; FEMALE; HEALTH STATUS INDICATORS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PATIENT DROPOUTS; PHENYLKETONURIAS; PROSPECTIVE STUDIES; REGISTRIES; TREATMENT OUTCOME;

EID: 0035040995     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(200105)44:5<1033::AID-ANR182>3.0.CO;2-G     Document Type: Article

References (50)

1. Borg G, Allander E, Lund B, Berg E, Brodin U, Pettersson H, et al. Aurunofin improves outcome in early rheumatoid arthritis: results from a 2-year double blind, placebo controlled study. J Rheumatol 1988;15:1747-54.
2. Van der Heijde DMFM, van Riel PLCM, van de Putte LBA. Sensitivity of a Dutch Health Assessment Questionnaire in a trial comparing hydroxychloroquine vs. sulphasalazine. Scand J Rheumatol 1990;19:407-12.
3. Kirwan JR. for the Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. N Engl J Med 1995;333:142-6.
4. Tugwell P, Pincus T, Yocum D, Stein M, Gluck O, Kraag G, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N Engl J Med 1995;333:137-41.
5. Van der Heide A, Jacobs JWG, Bijlsma WJ, Heurkens AHM, van Booma-Frankfort C, van der Veen MJ, et al. The effectiveness of early treatment with "second-line" antirheumatic drugs. Ann Intern Med 1996;124:699-707.
6. Strand V, Tugwell P, Bombardier C, Maetzel A, Crawford B, Dorrier C, et al. Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Arthritis Rheum 1999;42:1870-8.
7. Wilske KR, Healey LA. Remodeling the pyramid - a concept whose time has come. J Rheumatol 1989;16:565-7.
8. Fries JF. Reevaluating the therapeutic approach to rheumatoid arthritis: the "sawtooth" strategy. J Rheumatol 1990;17 Suppl 22:12-5.
9. Emery P. The optimal management of early rheumatoid disease: the key to preventing disability. Br J Rheumatol 1994;33:765-8.
10. Egsmose C, Lund B, Borg G, Pettersson H, Berg E, Brodin U, et al. Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study. J Rheumatol 1995;22:2208-13.
11. Boers M, Verhoeven AC, Markusse HM, van de Laar MAFJ, Westhovens R, van Denderen JC, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350:309-18.
12. Thompson PW, Kirwan JR, Barnes CG. Practical results of treatment with disease-modifying antirheumatoid drugs. Br J Rheumatol 1985;24:167-75.
13. Wolfe F, Hawley DJ, Cathey MA. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation in 1017 consecutive starts. J Rheumatol 1990;17: 994-1002.
14. Singh G, Fries JF, Williams CA, Zatarain L, Spitz P, Bloch DA. Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis. J Rheumatol 1991;18:188-94.
15. Pincus T, Marcum SB, Callahan LF. Long-term drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone. J Rheumatol 1992;19:1885-94.
16. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70:41-55.
17. D'Agostino RBJ. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;17:2265-81.
18. Symmons DPM, Barrett LM, Bankhead CR, Scott DGI, Silman A. The incidence of rheumatoid arthritis in the United Kingdom: results from the Norfolk Arthritis Register. Br J Rheumatol 1994;33:735-9.
19. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
20. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
21. Wiles N, Symmons DPM, Harrison B, Barrett E, Barrett JH, Scott DGI, et al. Estimating the incidence of rheumatoid arthritis: trying to hit a moving target? Arthritis Rheum 1999;42:1339-46.
22. Kirwan JR, Reeback JS. Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis. Br J Rheumatol 1986;25:206-9.
23. Joliffe IT. Principal component analysis and exploratory factor analysis. Stat Methods Med Res 1992;1:69-95.
24. Everitt BS, Dunn G. Factor analysis. In: Advanced methods of data exploration and modelling. London: Heinemann Educational Books; 1983. p. 191-210.
25. Hosmer DWJ, Lemeshow S. Applied logistic regression. New York: John Wiley & Sons; 1989.
26. Rosenbaum PR, Rubin DB. Assessing sensitivity to an unobserved binary covariate in an observational study with binary outcome. J Royal Stat Soc B 1983;45:212-8.
27. SPSS Inc. Statistical Package for the Social Sciences: version 9.0. Chicago: SPSS; 1999.
28. Stata Corporation. Stata statistical software: release 6.0. College Station (TX): Stata Corporation; 1999.
29. Brick JM, Kalton G. Handling missing data in survey research. Stat Methods Med Res 1996;5:215-38.
30. Fries JF, Williams CA, Morfeld D, Singh G, Sibley J. Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies. Arthritis Rheum 1996;39:616-22.
31. Pincus T. Rheumatoid arthritis: disappointing long-term outcomes despite successful short-term clinical trials [editorial]. J Clin Epidemiol 1988;41:1037-41.
32. Hawley DJ, Wolfe F. Are the results of controlled clinical trials and observational studies of second line therapy in rheumatoid arthritis valid and generalizable as measure of rheumatoid arthritis outcome: analysis of 122 studies. J Rheumatol 1991;18:1008-14.
33. Pincus T. Analyzing long-term outcomes of clinical care without randomized controlled clinical trials: the consecutive patient questionnaire database. Advances: J Mind Body Health 1997;13:3-32.
34. D'Agostino R, Kwan H. Measuring effectiveness: what to expect without a randomized control group. Med Care 1999;33 Suppl 4:AS95-105.
35. Myers WO, Marshfield WI, Gersh BJ, Fisher LD, Mock MB, Holmes DR, et al. Medical versus early surgical therapy in patients with triple-vessel disease and mild angina pectoris: a CASS registry study of survival. Ann Thorac Surg 1987;44:471-86.
36. Stone RA, Obrosky DS, Singer DE, Kapoor WN, Fine MJ, for The Pneumonia Patient Outcome Research Team (PORT) Investigators. Propensity score adjustment for pretreatment differences between hospitalized and ambulatory patients with community-acquired pneumonia. Med Care 1995;33 Suppl 4:AS56-66.
37. Connors AF, Speroff T, Dawson NV, Thomas C, Harrell FE, Wagner D, et al. The effectiveness of right heart catheterization in the initial care of critically ill patients. JAMA 1996;276:889-97.
38. Lieberman E, Lang JM, Cohen A, D'Agostino RJ, Datta S, Frigoletto FD. Association of epidural analgesia with cesarean delivery in nulliparas. Obstet Gynecol 1996;88:993-1000.
39. Intrator I, Berg K. Benefits of home health care after inpatient rehabilitation for hip fracture: health service use by Medicare beneficiaries, 1987-1992. Arch Phys Med Rehabil 1998;79:1195-9.
40. Van den Eeden S, Glasser M, Mathias S, Colwell HH, Pasta DJ, Kunz K. Quality of life, health care utilization, and costs among women undergoing hysterectomy in a managed-care setting. Am J Obstet Gynecol 1998;178:91-100.
41. Lytle BW, Blackstone EH, Loop FD, Houghtaling PL, Arnold JH, Akhrass R, et al. Two internal thoracic artery grafts are better than one. J Thorac Cardiovas Surg 1999;117:855-72.
42. Nakamura Y, Moss AJ, Brown MW, Kinoshita M, Kawai C. Long-term nitrate use may be deleterious in ischemic heart disease: a study using the databases from two large-scale postinfarction studies. Am Heart J 1999;138:577-85.
43. Nash IS, Corrato RR, Dlutowski MJ, O'Connor JP, Nash DB. Generalist versus specialist care for acute myocardial infarction. Am J Cardiol 1999;83:650-4.
44. Wolfe F, Cathey MA. Analysis of methotrexate treatment effect in a longitudinal observational study: utility of cluster analysis. J Rheumatol 1991;18:672-7.
45. Rothman KJ, Greenland S. Modern epidemiology. 2nd ed. Philadelphia: Lippincott-Raven; 1998.
46. Robins JM, Greenland S. Identifiability and exchangeability for direct and indirect effects. Epidemiology 1992;3:143-55.
47. Cook EF, Goldman L. Performance of tests of significance based on stratification by a multivariate confounder score or by a propensity score. J Clin Epidemiol 1989;42:317-24.
48. Drake C, Fisher L. Prognostic models and the propensity score. Int J Epidemiol 1995;24:183-7.
49. Drake C. Effects of misspecification of the propensity score on estimators of treatment effect. Biometrics 1993;49:1231-6.
50. McIntosh MW, Rubin DR. On estimating the causal effects of DNR orders. Med Care 1999;37:722-6.